FRISCO, Texas, March 31, 2015 (GLOBE NEWSWIRE) -- OxySure Systems, Inc. (OTCQB:OXYS) (“OxySure,” or the “Company”), today announced financial and operating results for the fourth quarter and year ended December 31, 2014.
Fiscal Year 2014 Highlights:
- Revenues were $2.4 million, up 35%, led by an 83% increase in revenues in the US
- 10th consecutive quarter of sales growth
- Gross profit was 56% on an adjusted basis
- General & administrative expense was $1.75 million
- Cash was at $647,093
- Capital leases decreased by $309,534
- Long term debt down 42%
- Working capital was a surplus of $418,734
- Current ratio was 1.3
- Total assets increased 7% to $2.5 million
- Net loss per share for the year was $0.10
- Model 615 shipments up 18%; Replacement cartridge shipments up 35%
- Replacement cartridges up to 144% of Model 615 shipped
Julian T. Ross, Chairman of the Board and Chief Executive Officer of OxySure stated, “We are pleased to have grown the business once again, while remaining focused on building a solid medical device platform to leverage growth opportunities going forward. We are now remarkably well-positioned as an emerging medical device leader to achieve our goals for 2015 and beyond. These goals include rapidly growing our direct sales force, expanding overseas, launching a direct to consumer (DTC) campaign, uplisting our company to NYSE or Nasdaq, and making strategic acquisitions.”
For the fiscal year ended December 31, 2014, revenues increased by 35% to $2,437,402 from $1,800,327 in 2013. The increase was primarily driven by an 83% surge in revenues in the United States. The revenue increase in the US was driven primarily by an increase in sales from products for the military in connection with a teaming agreement.
For the Company’s Model 615 portable emergency oxygen product, unit cartridge reorder rates continued to increase as the installed base of Model 615 increases, continuing the trend of a very “sticky” customer relationship with the product upon adoption. Unit cartridge shipments as a percentage of Model 615 shipments increased to 144% in FY2014 from 125% in FY2013. Cartridges as a percentage of the Model 615 installed base as at December 31, 2014 increased to 45%, up from 39.3% as at December 31, 2013. During FY2014, Model 615 shipments increased 18% versus FY2013, and replacement cartridge shipments increased 35% versus FY2013. This continues to be consistent with historical trends of rising reorders as customers become more accustomed to OxySure’s products.
Gross profit was $1,018,355 for the twelve months ended December 31, 2014, a decrease of 15.7% from $1,207,341, primarily due to the effect of an increase in absorbed rent expense and labor cost. Adjusted for these rent and labor expenses gross profit was $1,352,746 representing a gross margin of 56%.
Selling, general and administrative expenses for 2014 were $2,469,711 compared to $1,339,624 for fiscal year 2013. The Company increased sales and marketing expenses by 104% to $718,705 as it expanded its sales and marketing, branding and investor relations efforts. General and administrative expenses also increased by 78% to $1,751,006 primarily as a result of an increase in employee stock option expense, an increase in salaries and wages, and an increase in professional fees. Professional fees increased primarily due to legal and accounting fees related to an acquisition transaction the Company pursued during the second half of 2014 but did not consummate during FY2014.
Interest expense increased to approximately $907,612 in the twelve months ended December 31, 2014, as compared to $249,979 in the twelve months ended December 31, 2013, primarily as a result of the amortization of debt discount and beneficial conversion features (BCF). The Company recorded approximately $747,612 in non-cash interest related to debt discount amortization during the twelve months ended December 31, 2014, as compared to $207,239 during the twelve months ended December 31, 2013.
Net loss during fiscal year ended December 31, 2014 was $2,753,560, or $0.10 per share, as compared to $712,452 or $0.03 per share for fiscal year ended December 31, 2013. The weighted average shares outstanding were 26,367,254 and 23,754,402 for fiscal year 2014 and 2013, respectively.
The Company’s balance sheet remained strong. Cash was $647,093 at December 31, 2014 as compared to $657,673 at December 31, 2013. Working capital was a surplus of $418,734 at December 31, 2014 as compared to a surplus of $747,473 at December 31, 2013. The Company’s current ratio was 1.3 as at December 31, 2014. Cash from financing activities was down 24% to $1.16 million during FY2014 from $1.52 million during FY2013.
The Company had deferred income tax assets of $5,588,365 and $4,733,483 for the years ended December 31, 2014 and 2013 respectively which were offset in full by a valuation allowance.
Business updates
OxySure enters 2015 in a remarkably strong position as an emerging medical device leader. Over the past 12 months, the Company:
- Expanded its international distribution footprint by adding new distributors such as HTM Medico for Singapore, and Ajad Medical for Saudi Arabia;
- Received CE Mark Approval for the OxySure Model 615 Portable Emergency Oxygen Device, a critical step toward launching the product into the 30 countries belonging to the European Economic Area (EEA);
- Appointed several new US distributors;
- Commenced a pilot for a cloud-based tracking and incident reporting system;
- Made significant progress on the development of new products for the military;
- Secured Cliff Meidl, two-time Olympian and Team USA Olympic Flag Bearer to be a Spokesman and Special Advisor exclusively to the Company;
- Was selected by the United States Patent and Trademark Office (USPTO) as one of 10 companies, including Caterpillar, Qualcomm and others to exhibit its product and related technologies at the Innovation Expo held at the Smithsonian;
- Made significant staffing additions to enhance medical device platform capability, including a VP of Resuscitation Sales, Director of Regulatory Affairs and Quality Assurance, and additions in engineering, manufacturing and territory sales management; and
- Opportunistically invested in operational efficiencies.
The Company plans to continue its focus on growth by expanding its direct sales force and its global distribution channel. The Company also plans to ramp up its sales and marketing activities to raise market awareness and grow its brand, while maintaining a focus on regulatory approvals and compliance and reductions in product costs and operational costs. These initiatives and investments will result in higher sales for OxySure in the future, and at the same time expand OxySure’s leadership position in the emergency/short-duration oxygen market and the pre-hospital medical emergency market in general.
“We are excited about 2015 as we anticipate continued growth, new opportunities and even the possibility of catalytic events,” said Mr. Ross. “We plan to continue to work hard to improve our products, our competitive position, and our category leadership, while striving to maintain our culture of innovation as we grow.”
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
